United Statesblackstone.com/our-businesses/life-sciences
Blackstone Life Sciences is the life sciences investment and company-building platform of Blackstone. It focuses on financing and advancing development-stage therapeutics, medical technologies, and diagnostics, working with biopharmaceutical companies, emerging biotechs, and academic innovators to move promising assets from clinical development toward regulatory approval and commercialization.
The group provides long-term, structured capital and operational expertise, often through partnerships and project-specific financings that help de‑risk late-stage R&D. Its activities include creating new companies around high-potential assets, funding pivotal clinical trials, and supporting manufacturing readiness and market access planning. While not a manufacturer itself, Blackstone Life Sciences plays a significant role across the pharmaceutical value chain, influencing timelines and investment in drug development and related supply, including active pharmaceutical ingredients and specialized chemical processes critical to bringing new therapies to market.
None yet. When a new project in the record names Blackstone Life Sciences as owner, partner or investor, it shows here.
Q1 revenue $16.3B; KEYTRUDA $8.0B. GAAP loss $1.72/sh, non-GAAP loss $1.28/sh after $9.0B Cidara charge. Announced Terns acquisition; raised 2026 sales to $65.8-67.0B and non-GAAP EPS $5.04-5.16
Merck receives $700M from Blackstone for sac-TMT development, retaining control over its progress and commercialization.
